Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597315 | 1.00 | MAOB (0.57) | MAOBALOX5LCKLMNACYP1A2 | |
| SCHEMBL8618479 | 0.89 | GSTP1 (0.48) | MAOBALOX5LCKMAOACTSV | |
| SCHEMBL8616533 | 0.89 | GSTP1 (0.48) | MAOBALOX5LCKMAOACTSV | |
| SCHEMBL8613875 | 0.89 | GSTP1 (0.48) | MAOBALOX5LCKMAOACTSV | |
| SCHEMBL8616319 | 0.87 | GSTP1 (0.53) | MAOBALOX5LCKLMNACYP1A2 | |
| SCHEMBL8614981 | 0.87 | GSTP1 (0.53) | MAOBALOX5LCKLMNACYP1A2 | |
| SCHEMBL15688265 | 0.87 | MAOB (0.44) | MAOBALOX5LCKLMNACYP1A2 | |
| SCHEMBL8614759 | 0.86 | GSTP1 (0.49) | MAOBALOX5MAOAMAPTCTSV | |
| SCHEMBL30065009 | 0.86 | MAOB (0.57) | MAOBALOX5LMNACYP1A2PTGS1 | |
| SCHEMBL8251097 | 0.86 | MAOB (0.57) | MAOBALOX5LMNACYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720071-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-05-15 | — | — | US | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| US-6666989-B1 | Electrical and electro-optic apparatus comprising spaced glass panels having polyethers and electrodes on the interior surfaces, used as detectors, screens and in nonlinear optical apparatus | QINETIQ LIMITED (GB) | 2003-12-23 | — | — | US | disclosed |
| EP-1060226-A1 | LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999043763-A1 | LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1999-09-02 | — | — | WO | disclosed |
| US-5716542-A | Liquid crystal compound and liquid crystal composition containing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0739884-A2 | Liquid crystal compound and liquid crystal composition containing the same | Takasago International Corporation (JP) | 1996-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | MAOB 3747/4885ALOX5 4330/4885LCK 1279/4885 |
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR84, GPR68 | MAOB 1932/4885ALOX5 3773/4885LCK 1372/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | MAOB 958/4885ALOX5 1336/4885LCK 4330/4885 |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | MAOB 3214/4885ALOX5 3336/4885LCK 1218/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | MAOB 3146/4885ALOX5 3359/4885LCK 1551/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAOB 4027/4885ALOX5 3343/4885LCK 2674/4885 |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR68, HTR2A | MAOB 1607/4885ALOX5 4107/4885LCK 1852/4885 |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | MAOB 3275/4885ALOX5 4563/4885LCK 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.